Strategic Report Corporate Governance Financial Statements Additional Information Index 2013 performance summary 2 Infection 61, 62 Accounting policies 136, 189 Inflammation see Respiratory, Inflammation and Autoimmunity Acquisitions and disposals 166 Intangible assets 80, 85, 100, 150 Amgen 60, 81 Intellectual Property 72 Amylin 8, 54, 66, 152 Interest-bearing loans and borrowings 156 Animals 39 Inventories 138, 155 Annual general meeting 91, 92, 96, 101, 103, 114 Key performance indicators 20 Ardea 60 Leases 183 Articles of association 230 Life-cycle of a medicine 34 Audit Committee 92, 98 Litigation 177 Biologics 5, 14, 15, 16, 33, 34, 36, 48 Manufacturing and Supply 43 BMS 5, 7, 8, 54, 66, 70, 73, 184 Market definitions 232 Board 26, 28 Neuroscience 61, 62 Branches 95 Nomination and Governance Committee 26, 93 Business background and results overview 75 Oncology 32, 37, 56 Business model 10 Operating profit 77 Capitalisation and shareholder return 82 Operational overview 4 Cardiovascular and Metabolic disease 46, 52 Other investments 139, 154 Cash and cash equivalents 76, 139, 155 Patent expiries 198 Chairmans Statement 6 Patents see Intellectual Property Chief Executive Officers Review 8 Patient safety 38 Clinical trials 39 Pharmaceutical industry 13 Code of Conduct 92, 95, 98 Pipeline 4, 48-51, 194 Commitments and contingent liabilities 176 Political donations 96 Community investment 70, 71 Post-retirement benefits 159 Company history 230 Pricing 15, 41, 214 Competition 13 Principal risks and uncertainties 200 Compliance and Internal Audit Services 94, 199 Product revenue information 141, 214 Consolidated statement of Cash Flows 135 Property, plant and equipment 80, 138, 148, 223 Consolidated statement of Changes in Equity 134 Provisions for liabilities and charges 158 Consolidated statement of Comprehensive Income 132 Regulatory requirements 14 Consolidated statement of Financial Position 133 Related party transactions 184 Corporate governance 26, 88 Relations with shareholders 92 Corporate responsibility 220 Remuneration Committee 26, 92, 102 Diabetes 18, 52 Research and Development 36 Directors interest in shares 110 Reserves 165 Directors remuneration 26, 102 Respiratory, Inflammation and Autoimmunity 58 Directors responsibility statement 127 Restructuring 16 Diversity 67, 68, 89 Results of operations 2012 222 Dividends 5, 95, 165, 227, 228 Results of operations 2013 77 Earnings per Ordinary Share 4, 146 Revised Core financial measures 224 Emerging Markets 18, 41, 69, 203, 214, 221 Risks 24, 199 Employee costs and share plans for employees 173 Sales and Marketing 40 Employees 66 Sales by geographical area 214 Ethics 38, 39, 42, 94, 200, 220 Sales by therapy area 214 Finance income and expense 143 Science Committee 26, 93 Financial instruments 139, 142, 143 Segment information 146 Financial position 2012 223 Senior management SET 30 Financial position 2013 80 Share capital 165, 191 Financial risk management 82 Share repurchase 82, 165 Financial summary 2 Shareholder information 225 Gastrointestinal 61, 63 Specialty care 2, 48 Gender 67, 68, 89 Statutory and other information 184 Glossary 232 Strategic priorities 16 Goodwill 80, 137, 149 Subsidiaries 186 Group Financial Record 193 Taxation 83, 144, 189, 213 Group Financial Statements 127 Taxation information for shareholders 227, 228, 229 Growth platforms 4, 18 Trade and other payables 138, 158 Health and safety 69, 220 Trade and other receivables 138, 155 Human Rights 68 Trade marks 231 Independent auditors report 128 World pharmaceutical markets 13 AstraZeneca Annual Report and Form 20-F Information 2013 235 Additional Information Important information for readers of this Annual Report Cautionary statement regarding Inclusion of Reported performance, AstraZeneca websites forward-looking statements Core financial measures and constant Information on or accessible through our The purpose of this Annual Report is to exchange rate growth rates websites, including www.
com, provide information to the members of the AstraZenecas determination of non-GAAP www.
The Company and its Directors, measures together with our presentation www.
com, does not form employees, agents and advisers do not of them within our financial information may part of and is not incorporated into this accept or assume responsibility to any differ from similarly titled non-GAAP Annual Report.
other person to whom this Annual Report measures of other companies.
External third party websites is shown or into whose hands it may come Statements of competitive position, Information on or accessible through any and any such responsibility or liability is growth rates and sales third party or external website does not expressly disclaimed.
In order, among In this Annual Report, except as otherwise form part of and is not incorporated into other things, to utilise the safe harbour stated, market information regarding this Annual Report.
provisions of the US Private Securities the position of our business or products Figures Litigation Reform Act of 1995 and the UK relative to its or their competition is based Figures in parentheses in tables and in the Companies Act 2006, we are providing the upon published statistical sales data Financial Statements are used to represent following cautionary statement: This Annual for the 12 months ended 30 September negative numbers.
Report contains certain forward-looking 2013 obtained from IMS Health, a statements with respect to the operations, leading supplier of statistical data to performance and financial condition of the the pharmaceutical industry.
Unless Group, including, among other things, otherwise noted, for the US, dispensed statements about expected revenues, new or total prescription data and audited margins, earnings per share or other sales data are taken, respectively, from financial or other measures.
ForwardIMS Health National Prescription Audit looking statements are statements and IMS National Sales Perspectives for relating to the future which are based the 12 months ended 31 December 2013: on information available at the time such such data is not adjusted for Medicaid and statements are made, including information similar rebates.
At the time of production relating to risks and uncertainties.
Although of this Annual Report, AstraZeneca we believe that the forward-looking understands that IMS Health intends statements in this Annual Report are to restate its published US sales data based on reasonable assumptions, the for the 12 months ended 30 September matters discussed in the forward-looking 2013, with such restatement to take place in statements may be influenced by factors March 2014.
While it has not been possible that could cause actual outcomes and to revise the data in this Annual Report results to be materially different from those based on such restated data, AstraZeneca expressed or implied by these statements.
understands had it been possible that the The forward-looking statements reflect impact on the market information included knowledge and information available at in this Annual Report would not have been the date of the preparation of this Annual significant or material.
Except as otherwise Report and the Company undertakes no stated, these market share and industry obligation to update these forward-looking data from IMS Health have been derived statements.
We identify the forward-looking by comparing our sales revenue to statements by using the words anticipates, competitors and total market sales believes, expects, intends and similar revenues for that period.
Except as expressions in such statements.
Important otherwise stated, growth rates are given factors that could cause actual results to at CER.
For the purposes of this Annual differ materially from those contained in Report, unless otherwise stated, references forward-looking statements, certain of to the world pharmaceutical market or which are beyond our control, include, similar phrases are to the 54 countries among other things, those factors identified contained in the IMS Health database, in the Principal risks and uncertainties which amounted to approximately section from page 200 of this Annual 92% in value of the countries audited Report.
Nothing in this Annual Report by IMS Health.
should be construed as a profit forecast.
236 AstraZeneca Annual Report and Form 20-F Information 2013 Registered office and Registrar corporate headquarters Equiniti Limited AstraZeneca PLC Aspect House 2 Kingdom Street Spencer Road London W2 6BD Lancing UK West Sussex BN99 6DA Tel: 44 0 20 7604 8000 UK Fax: 44 0 20 7604 8151 Tel: freephone in the UK 0800 389 1580 Investor relations Tel: outside the UK ir@astrazeneca.
com 44 0 121 415 7033 UK: as above Swedish Central Securities Depository US Euroclear Sweden AB Investor Relations PO Box 191 AstraZeneca Pharmaceuticals LP SE-101 23 Stockholm 1800 Concord Pike Sweden PO Box 15437 Tel: 46 0 8 402 9000 Wilmington fide 19850-5437 US Depositary US JPMorgan Chase & Co Tel: 1 302 886 3000 PO Box 64504 Fax: 1 302 886 2972 St Paul MN 55164-0504 US Tel: toll free in the US 800 990 1135 Tel: outside the US 1 651 453 2128 jpmorgan.
com Designed and produced by Board, SET and portrait photography by Marcus Lyon This Annual Report is printed on Heaven 42 which is FSC certified virgin fibre.
The pulp is a mix, partly bleached using an Elemental Chlorine Free ECF process and partly bleached using a Totally Chlorine Free process.
Printed in the UK by Pureprint using its and environmental printing technology, and vegetable inks were used throughout.
Both the manufacturing mill and the printer are registered to the Environmental Management System ISO14001 and are Forest Stewardship Council chain-of-custody certified.
AstraZeneca Annual Report and Form 20-F Information 2013 This Annual Report is also available on our website, www.
